ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
A Guernsey resident believes "people's enjoyment in life" is being sacrificed for the financial cost of using a drug that can treat wet age-related macular degeneration (AMD).
EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...
A single intravitreal injection of 4D-150 helped patients with wet age-related macular degeneration maintain visual acuity ...
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher ...
Please provide your email address to receive an email when new articles are posted on . Driving distance was inversely associated with the average number of injections per year. Travel reimbursement ...
Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...
Wet age-related macular degeneration (AMD) is an eye condition that threatens the middle of your eyesight. It’s caused when abnormal blood vessels in your eyes leak fluid, damaging the part of your ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback